Making earlier cancer detection a routine part of medical care
EXACT SCIENCES
Revenue
Operating expenses
Cost of sales (exclusive of amortization of acquired intangible assets)
Research and development
Sales and marketing
General and administrative
Amortization of acquired intangible assets
Impairment of long-lived assets
Total operating expenses
Other operating loss
Loss from operations
Other income (expense)
Investment income (loss), net
Interest expense
Total other income (expense)
Net loss before tax
Income tax benefit
Net loss
EXACT SCIENCES CORPORATION
Selected Unaudited Financial Information
Condensed Consolidated Statements of Operations
(Amounts in thousands, except per share data)
Net loss per share-basic and diluted
Weighted average common shares outstanding basic and diluted
Three Months Ended September
30,
$
$
2022
147,937
90,813
187,697
191,968
23,526
5,946
647,887
523,073 $ 456,379 $
(13,244)
(138,058)
(8,584)
(5,235)
(13,819)
(151,877)
3,116
(148,761) $
(0.84)
2021
176,997
115,738
75,356
196,617
186,541
23,940
20,210
618,402
(4,093)
(4,680)
(8,773)
(170,796)
(13,244)
(162,023) (474,629)
3,858
Nine Months Ended September
30,
(166,938)
(0.97) $
171,978
2022
2021
1,531,284 $ 1,293,275
427,242
299,144
635,800
543,410
74,536
12,537
1,992,669
(13,790)
(14,224)
(28,014)
(502,643)
6,882
(495,761) $
(2.82) $
175,935
339,699
297,158
577,585
621,897
70,954
20,210
1,927,503
(634,228)
30,524
(13,948)
16,576
(617,652)
242,638
(375,014)
(2.19)
170,978
14View entire presentation